ABBVIE INC. (NYSE:ABBV) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.Submission of Matters to a Vote of Security Holders.
AbbVie Inc. (AbbVie) held its Annual Meeting of Stockholders on
May5, 2017. The following is a summary of the matters voted on at
that meeting.
(1) The stockholders elected AbbVies ClassII Directors with terms
expiring in 2020, as follows:
|
Name |
|
For |
|
Against |
|
BrokerNon-Votes |
|
Robert J. Alpern |
1,118,328,511 |
10,737,541 |
280,277,501 |
|||
|
Edward M. Liddy |
1,113,185,998 |
15,880,054 |
280,277,501 |
|||
|
Melody B. Meyer |
1,121,539,612 |
7,526,440 |
280,277,501 |
|||
|
Frederick H. Waddell |
1,119,615,307 |
9,450,745 |
280,277,501 |
(2) The stockholders ratified the appointment of Ernst Young LLP
as AbbVies independent registered public accounting firm for
2017, as follows:
|
For |
|
Against |
|
Abstain |
|
1,392,413,822 |
14,065,091 |
2,864,640 |
(3) The stockholders approved, on an advisory basis, the
compensation of AbbVies named executive officers listed in the
proxy statement for the 2017 annual meeting, as follows:
|
For |
|
Against |
|
Abstain |
|
BrokerNon-Votes |
|
1,066,989,000 |
50,885,097 |
11,191,955 |
280,277,501 |
(4) The stockholders did not approve the management proposal
regarding amendment of the certificate of incorporation for the
annual election of directors, as follows:
|
For |
|
Against |
|
Abstain |
|
BrokerNon-Votes |
|
1,116,988,345 |
7,082,900 |
4,994,807 |
280,277,501 |
(5) The stockholders did not approve a stockholder proposal to
issue a lobbying report, as follows:
|
For |
|
Against |
|
Abstain |
|
BrokerNon-Votes |
|
280,902,158 |
774,007,636 |
74,156,258 |
280,277,501 |
(6) The stockholders did not approve a stockholder proposal to
separate chair and CEO, as follows:
|
For |
|
Against |
|
Abstain |
|
BrokerNon-Votes |
|
386,900,232 |
735,332,171 |
6,833,649 |
280,277,501 |
About ABBVIE INC. (NYSE:ABBV)
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women’s health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products. ABBVIE INC. (NYSE:ABBV) Recent Trading Information
ABBVIE INC. (NYSE:ABBV) closed its last trading session down -0.04 at 66.17 with 4,497,397 shares trading hands.
